

# Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

## LN-319

RRID:CVCL\_3958

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_3958

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_3958](https://web.expasy.org/cellosaurus/CVCL_3958)

**Proper Citation:** RRID:CVCL\_3958

**Description:** Cell line LN-319 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Astrocytoma

**Defining Citation:** [PMID:7693337](#), [PMID:7732013](#), [PMID:9842975](#), [PMID:10416987](#), [PMID:14614447](#), [PMID:14655754](#), [PMID:17595512](#), [PMID:21406405](#), [PMID:22570425](#), [PMID:25984343](#), [PMID:30894373](#), [PMID:31068700](#)

**Comments:** Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Contaminated. Shown to be a LN-992 derivative (PubMed=22570425)..

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** LN-319

**Synonyms:** LN 319, LN319

**Cross References:** BTO:BTO\_0002215, AddexBio:C0005001/54, BioSample:SAMN03151824, BioSample:SAMN10988411, cancercellines:CVCL\_3958, Cell\_Model\_Passport:SIDM01626, Cosmic:849864, Cosmic:2367493, Cosmic:2516027, DepMap:ACH-000128, GEO:GSM397667, GEO:GSM397668, IARC\_TP53:2572, PharmacDB:LN319\_843\_2019, Wikidata:Q54902776

**ID:** CVCL\_3958

**Hierarchy:** cvcl\_6845

**Record Creation Time:** 20220427T220731+0000

**Record Last Update:** 20260815T234508+0000

---

## Ratings and Alerts

No rating or validation information has been found for LN-319.

**Warning:** Problematic cell line: Contaminated. Shown to be a LN-992 derivative (PubMed=22570425).

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00450.

Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Contaminated. Shown to be a LN-992 derivative (PubMed=22570425)..

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Sallbach J, et al. (2024) The cell cycle inhibitor p21CIP1 is essential for irinotecan-induced senescence and plays a decisive role in re-sensitization of temozolomide-resistant glioblastoma cells to irinotecan. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 181, 117634.

Khadka S, et al. (2023) Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolism. *bioRxiv : the preprint server for biology*.

Zhang M, et al. (2020) Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma. *Frontiers in genetics*, 11, 363.

Zhang M, et al. (2020) Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma. *Frontiers in genetics*, 11, 441.

von Achenbach C, et al. (2020) Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models. *Journal of neurochemistry*, 153(4), 510.

von Achenbach C, et al. (2018) Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. *Journal of neurochemistry*, 147(1), 99.